Deal Watch: Pfizer Lays Groundwork In Gene Therapy
Executive Summary
Pfizer expands its position in rare diseases in a collaboration with Spark Therapeutics and also licenses a pair of preclinical oncology candidates from Belgium’s iTeos Therapeutics. Meanwhile, Shire gets $15 million in research funding from the Cystic Fibrosis Foundation to help advance a novel aerosolized therapy addressing the underlying cause of CF.
You may also be interested in...
CSL/UniQure’s Hemgenix To Enter Uncertain EU Market After Regulatory Nod
The firms’ one-time hemophilia B gene therapy has been approved in the EU just months after a US nod, but concerns remain about its prospects on a market that has seen several setbacks for other gene therapies.
Pfizer’s Gene Therapy Asset Chases UniQure/CSL’s Hemgenix After Pivotal Hemophilia B Success
Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.